Financial Performance (Consolidated, Rs. Million)

Q2 FY2027 Results:

  • Revenue from Operations: ₹2,553.9 million (vs. ₹2,015.6 million in Q2 FY26), up 26.7% YoY
  • EBITDA: ₹1,127.5 million (vs. ₹818.3 million in Q2 FY26), up 37.8% YoY
  • EBITDA Margin: 44.1% (vs. 40.6% in Q2 FY26), improvement of 355 bps
  • Profit after Tax (PAT): ₹594.7 million (vs. ₹432.8 million in Q2 FY26), up 37.4% YoY
  • PAT Margin: 23.3% (vs. 21.5% in Q2 FY26), improvement of 181 bps

H1 FY2027 Results:

  • Revenue from Operations: ₹4,863.7 million (vs. ₹3,896.1 million in H1 FY26), up 24.8% YoY
  • EBITDA: ₹2,112.9 million (vs. ₹1,553.6 million in H1 FY26), up 36.0% YoY
  • EBITDA Margin: 43.4% (vs. 39.9% in H1 FY26), improvement of 357 bps
  • Profit after Tax (PAT): ₹1,125.7 million (vs. ₹818.7 million in H1 FY26), up 37.5% YoY
  • PAT Margin: 23.1% (vs. 21.0% in H1 FY26), improvement of 213 bps

Operational Highlights

Q2 FY2027:

  • Total Tests: 4.98 million (vs. 4.28 million in Q2 FY26), up 16.5% YoY
  • Total Footfall: 1.37 million (vs. 1.20 million in Q2 FY26), up 14.5% YoY
  • Tests per Footfall: 3.64 (vs. 3.57 in Q2 FY26), up 1.7% YoY
  • Average realization per test: ₹513 (vs. ₹471 in Q2 FY26), up 8.8% YoY
  • Average realization per Footfall: ₹1,865 (vs. ₹1,685 in Q2 FY26), up 10.6% YoY
  • Wellness share: 14.5% (vs. 14.4% in Q2 FY26), improvement of 4 bps

H1 FY2027:

  • Total Tests: 9.57 million (vs. 8.22 million in H1 FY26), up 16.5% YoY
  • Total Footfall: 2.61 million (vs. 2.30 million in H1 FY26), up 13.7% YoY
  • Tests per Footfall: 3.67 (vs. 3.58 in H1 FY26), up 2.5% YoY
  • Average realization per test: ₹508 (vs. ₹474 in H1 FY26), up 7.2% YoY
  • Average realization per Footfall: ₹1,862 (vs. ₹1,696 in H1 FY26), up 9.8% YoY
  • Wellness share: 14.6% (vs. 14.3% in H1 FY26), improvement of 29 bps

Business Outlook and Management Commentary

Ms. Suprita Reddy, MD & CEO, commented on the business performance and outlook:

  • Sustained strong growth momentum with 26.7% YoY revenue growth supported by 16.5% volume growth
  • Existing centres grew by approximately 20%, while newer centres continued to ramp up well
  • Core markets maintained strong momentum, Pune showing meaningful turnaround with consistent double-digit growth
  • Encouraging momentum in West Bengal with strengthening brand awareness
  • Positive response in Tier-II markets including Krishnanagar and Diamond Harbour

Expansion and Acquisition Update

  • Commissioned 2 hubs and 7 spokes during H1 FY27
  • Plans to commission another 3 hubs and 7 spokes in H2 FY27
  • Additional 3 hubs planned for Q1 FY28
  • Entered into Business Transfer Agreement to acquire Arya Wellness Centre in Guwahati, Assam
  • Marks entry into North-East region, providing platform to establish presence in Guwahati and explore growth opportunities across North-East

Company Background

Vijaya Diagnostic Centre Limited is one of India's largest integrated diagnostic chains with:

  • 165+ diagnostic centres and 29 reference laboratories
  • Presence in 27 cities and towns across Telangana, Andhra Pradesh, Maharashtra, Karnataka, NCR and West Bengal
  • Comprehensive diagnostic services from basic pathology to high-end radiology
  • Corporate Identification No: L85195TG2002PLC039075